Full-Life Technologies Announces U.S. FDA IND Clearance and Australian Regulatory Clearance for [²²⁵Ac]Ac-FL-261 Phase 1 Clinical Trial

Full-Life Technologies ("Full-Life", the "Company"), a privately held, fully integrated, clinical-stage actinium-based global radiopharmaceutical company, today announced that the U.S. Food and Drug A ...
Yahoo Finance

Full-Life Technologies Announces US$77 Million Financing to Accelerate Development of its Radiopharmaceutical Pipeline and Manufacturing Capabilities

Additional debt financing provides an alternative financing solution for Full-Life's future development CHENGDU, China and GEMBLOUX, Belgium, Sept. 29, 2025 /PRNewswire/ -- Full-Life Technologies ...
BioWorld

Full-Life’s [225Ac]Ac-FL-261 cleared for clinic in US, Australia

Full-Life Technologies Ltd. has obtained regulatory clearances in the U.S. and Australia for a first-in-human phase I trial of [225Ac]Ac-FL-261 in patients with c-MET-expressing non-squamous non-small ...
BioWorld

Full-Life acquires Focus-X in $245M deal to expand radiopharmaceuticals pipeline

Full-Life Technologies Ltd. reported that it will acquire Focus-X Therapeutics Inc. to expand its radiopharmaceutical oncology therapy pipeline in a deal worth up to $245 million.